Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..
SYS-CON.TV
Today's Top SOA Links


Edison Pharmaceuticals & Bambino Gesu Children's Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
First subject enrolled in double-blind placebo-controlled trial

MOUNTAIN VIEW, Calif., Feb. 19, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2 clinical trial entitled, "Double-Blind, Placebo-Controlled Clinical Trial of EPI-743 in Patients with Cobalamin C Defect."

The trial is a placebo-controlled study lasting 12 months, preceded by a six-month run-in phase for all patients to establish a defined clinical and metabolic baseline. The primary endpoint is improvement in visual function with secondary outcome measurements assessing neurologic and neuromuscular function, glutathione biomarkers, quality of life, as well as safety parameters. More information on study specifics is available at www.ClinicalTrials.gov.

The rationale underlying this investigation is centered on understanding whether EPI-743 – a therapeutic targeting primary defects in electron transport– might hold therapeutic benefit in disorders of intermediary metabolism that also result in redox disturbances.

"Cobalamin C deficiency represents an inherited disorder that induces perturbations in the metabolism of glutathione. Given the central role of glutathione in cellular redox balance and antioxidant defense systems, we are eager to explore whether a therapeutic that increases glutathione such as EPI-743 will provide clinical benefit," stated Professor Carlo Dionisi-Vici, Division of Metabolism, Bambino Gesu Children's Hospital– the trial's principal investigator. 

Cobalamin C Deficiency Syndrome

Cobalamin C (Cbl-C) defect belongs to the family of diseases known as methylmalonic acidurias and is the most common inborn error of vitamin B12 metabolism. Cbl-C defect is a syndrome that results in multiorgan system disease most significantly impacting the central nervous system. While the clinical presentation can be heterogeneous, the onset of symptoms typically arises within the first year of life and includes seizures, hypotonia, hydrocephalus, developmental delay, and failure to thrive. Visual impairment results from retinal atrophy and oculomotor defects. Cardiovascular disease, hemolytic uremic syndrome, and gastrointestinal involvement may also occur. A smaller subset of patients may present later in childhood or early adulthood and typically have a milder phenotype with neurological and vascular manifestations. 

Cbl-C defect is an autosomal recessive disorder with an estimated incidence of 1:60,000 to 1:100,000. The gene responsible for the Cbl-C defect is known as MMACHC and is located on chromosome 1p. On a biochemical level, the Cbl-C defect prevents the conversion of vitamin B12 into its most important metabolically active forms—methylcobalamin and adenosylcobalamin. This in turn leads to the accumulation of methylmalonic acid and homocysteine as well as to the reduced synthesis of methionine. It is believed that the accumulation of methylmalonic acid and homocysteine, along with reduced synthesis of methionine, results in increased cellular oxidative stress and to perturbation in glutathione metabolism — a critical and endogenous cellular antioxidant. 

Despite existing vitamin replacement therapies, biochemical abnormalities never fully normalize and there is an unsatisfactory impact on the neurologic outcome. 

EPI-743

EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of Friedreich's ataxia and other inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress.

Edison Pharmaceuticals
Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children and adults with orphan mitochondrial diseases.

SOURCE Edison Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE